Vault Complex Fusion Peptide Hydrophobic Drug Sequestration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems face limitations due to the poor pharmacokinetic and pharmacodynamic properties of hydrophobic drugs, particularly those with poor aqueous solubility, and existing nanoparticle-based platforms like dendrimers and liposomes have size limitations and lack tissue targeting capabilities.
Innovation Solution
Development of a vault complex comprising a modified major vault protein with a fusion peptide fused to its N-terminus, which enhances the sequestering of hydrophobic and aqueous insoluble therapeutic compounds within the vault complex, providing improved affinity and targeting capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional drug delivery systems (dendrimers, liposomes) are used, then drug delivery is achieved, but size limitations and lack of tissue targeting occur
Solution Approach 1:
The vault complex is engineered to perform multiple functions simultaneously: it provides a protective nanoparticle structure, enables tissue targeting through surface modifications, and facilitates drug loading through its unique internal cavity structure. This multi-functionality resolves the contradiction by integrating targeting and delivery capabilities into a single platform without proportionally increasing complexity.
Solution Approach 2:
The patent utilizes the nested structure of the vault complex, where the internal cavity accommodates therapeutic compounds while the external surface can be modified with targeting ligands. This nested architecture allows the particle to simultaneously house drugs and provide targeting functionality without requiring separate structural elements, thereby reducing overall complexity.
2Reliability
If hydrophobic drugs are administered, then therapeutic effect is achieved, but poor aqueous solubility causes pharmacokinetic issues
Solution Approach 1:
The vault complex acts as an intermediary carrier that bridges the hydrophobic drug and the aqueous biological environment. The nanoparticle's core structure accommodates hydrophobic compounds while its surface properties enable aqueous solubility and biological compatibility, thus mediating between the incompatible hydrophobic drug and aqueous physiological conditions.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the drug delivery system by engineering the vault complex with specific surface properties and internal cavity characteristics. These parameter changes enable the particle to simultaneously provide a hydrophobic microenvironment for drug stability and aqueous compatibility for biological delivery, resolving the solubility issue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vault complex effectively sequesters and delivers hydrophobic compounds, offering enhanced solubility and targeting, leading to improved therapeutic efficacy with reduced systemic exposure and localized delivery.
Implementation Method 1
the fusion peptide binds the therapeutic compound non-covalently and/or binds a lipophilic substance non-covalently, providing an increased affinity of the therapeutic compound to the inside of the vault complex
Data Source
AI summary
The invention relates to compositions of vault complexes for use as delivery agents for hydrophobic and/or aqueous insoluble therapeutic compounds. In one aspect, provided herein is a vault complex comprising a modified major vault protein (MVP), wherein the modified major vault protein comprises a fusion peptide, wherein said fusion peptide is fused to the N-terminus of the major vault protein, and wherein said peptide provides enhanced sequestering of a hydrophobic and/or aqueous insoluble therapeutic compound within the vault complex.